140 episodes

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast PVI, PeerView Institute for Medical Education

    • Science
    • 4.2, 6 Ratings

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Matthew S. Johnson, MD, FSIR - Teaming Up to Improve Liver Cancer Outcomes Through Locoregional and Systemic Therapeutic Strategies: A Multidisciplinary Tumor Board Guiding Optimal Care for Patients Along the Intermediate to Advanced Disease Continuum

    Matthew S. Johnson, MD, FSIR - Teaming Up to Improve Liver Cancer Outcomes Through Locoregional and Systemic Therapeutic Strategies: A Multidisciplinary Tumor Board Guiding Optimal Care for Patients Along the Intermediate to Advanced Disease Continuum

    Go online to PeerView.com/DWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hepatocellular carcinoma (HCC) is a complex liver malignancy for which a variety of treatment modalities, based on disease stage and patient factors, are available. Traditionally, interventional radiologists (IR) have had a key role in managing intermediate-stage disease through the use of locoregional approaches, while oncologists have employed systemic therapy in the realm of advanced-stage disease. However, an improved understanding of HCC pathology has led to the realization that optimal approaches to selecting, combining, sequencing, and transitioning between different modalities has the potential to improve outcomes across disease settings, underscoring the importance of a multidisciplinary team-based approach to HCC management. As approvals for new drugs (eg, TKIs, antiangiogenic agents, immunotherapy, combinations) and positive clinical trial outcomes with novel multimodal strategies continue to impact the HCC treatment paradigm, clinical decision-making has become complicated, with many questions arising about optimal approaches to administering various therapies to the appropriate patient in a timely manner within a team-based care model. In this CME-certified online activity, a multidisciplinary panel of interventional radiology, hepatology, and oncology experts offers insights on how to navigate the intermediate- to advanced-stage HCC landscape in an era of evolving treatment—from use of modern IR approaches to newer systemic therapies and combination strategies—to provide the most benefit for patients with HCC. Upon completion of this activity, participants should be better able to: Review pivotal clinical evidence on newly available systemic treatment options, including multikinase inhibitors, antiangiogenic agents, and checkpoint inhibitors, for newly diagnosed and previously treated patients with advanced HCC, Examine the potential role of combination systemic therapy approaches (eg, dual immune checkpoint blockade, immunotherapy plus targeted therapy) for advanced HCC, Assess emerging evidence on novel multimodal approaches for intermediate- and advanced-stage HCC, Develop optimal multidisciplinary treatment plans based on available evidence, patient- and disease-related factors, and recommendations on timely transitions from locoregional to systemic options for patients with intermediate or advanced HCC.

    • 1 hr 18 min
    Joyce O’Shaughnessy, MD - Evidence Informing Practice: Changing Standards of Care for Use of CDK4 and 6 Inhibitors in the Treatment of Breast Cancer

    Joyce O’Shaughnessy, MD - Evidence Informing Practice: Changing Standards of Care for Use of CDK4 and 6 Inhibitors in the Treatment of Breast Cancer

    Go online to PeerView.com/BKK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, breast cancer experts discuss the latest evidence on the use of CDK4 and 6 inhibitors in the management of patients with HR-positive, HER2-negative breast cancer. An essential overview of mechanisms of action of this therapeutic class, similarities/differences among the agents, and latest approvals/indications is provided, along with a summary and analysis of the current state of the science. Practicalities of clinical integration of the CDK4 and 6 inhibitors are also explored, with a focus on navigating the current treatment landscape and making individualized clinical decisions. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanism of action, and characteristics (including similarities/differences) of the CDK4 and 6 inhibitors in breast cancer, Analyze the latest efficacy (including OS), safety, and other key data from clinical trials assessing CDK4 and 6 inhibitors in breast cancer, and relevant implications for clinical practice, Discuss the relevant patient-, disease-, and treatment-related factors as well as promising prognostic/predictive biomarkers that could be used to guide selection of patients who would benefit from CDK4 and 6 inhibitors, Incorporate CDK4 and 6 inhibitors alone or in combination into treatment plans for appropriate patients with hormone receptor–positive, HER2-negative advanced breast cancer according to relevant evidence, clinical guidelines, predictive factors, and patient needs and preferences, Manage treatment-related toxicities in patients with breast cancer undergoing treatment with CDK4 and 6 inhibitors to maintain optimal adherence and promote favorable outcomes.

    • 1 hr 17 min
    Kimberly Halla, MSN, FNP-C - Rethinking Patient Care in Endometrial and Cervical Cancer: How Nurses Can Lead the Targeted and Immunotherapeutic Revolution

    Kimberly Halla, MSN, FNP-C - Rethinking Patient Care in Endometrial and Cervical Cancer: How Nurses Can Lead the Targeted and Immunotherapeutic Revolution

    Go online to PeerView.com/FDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CNE activity, a family nurse practitioner brings the nurse’s perspective to patient care in endometrial and cervical cancer. Kimberly Halla, MSN, FNP-C, discusses modern management techniques for patient’s receiving targeted therapy and immunotherapy, as well as combination therapies, and gives her take on how to approach the unique safety profiles associated with these treatment options. Upon completion of this activity, participants will be able to: Summarize the current treatment and regulatory landscape in the management of gynecologic cancers, including the role of novel targeted, immunotherapeutic, and combination approaches in cervical and endometrial cancers, Describe safety and efficacy evidence surrounding targeted, immune checkpoint inhibitor, and combination strategies for the management of gynecologic cancers, Educate patients about therapeutic and safety considerations associated with recently approved and emerging options for endometrial and cervical cancers, Manage the unique spectrum of adverse events associated with targeted and immunotherapy used to treat endometrial and cervical cancers.

    • 35 min
    Sagar Lonial, MD, FACP - How I Think, How I Treat: Understanding Innovation in Multiple Myeloma—New Models for Attacking Disease Across the Clinical Spectrum

    Sagar Lonial, MD, FACP - How I Think, How I Treat: Understanding Innovation in Multiple Myeloma—New Models for Attacking Disease Across the Clinical Spectrum

    Go online to PeerView.com/XBQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert panel charts progress in myeloma care by discussing their personal experiences and insights, including analyses of how current evidence has informed the experts’ own practice along the disease continuum, from newly diagnosed to relapsed disease. This unique activity provides a link that connects novel agents to their applications in daily practice and clearly shows how novel antibodies, immunotherapy, and other innovative strategies have shaped a new model for myeloma care. Upon completion of this activity, participants should be better able to: Discuss updated practice guidelines and new efficacy and safety findings on the use of novel immunomodulating agents, proteasome inhibitors, antibodies, cell therapy, and targeted agents in the myeloma setting, Integrate novel therapeutics into the management of newly diagnosed myeloma, including for patients with smoldering disease or those with symptomatic disease regardless of transplant eligibility, Develop safe, personalized therapeutic platforms for patients with pretreated myeloma, including patients with an early relapse or those with heavily pretreated disease, Manage therapeutic safety, dosing, and monitoring considerations with novel treatment platforms in multiple myeloma.

    • 1 hr 9 min
    Arjun Balar, MD - Innovative Treatments for Bladder Cancer: Thoughts From the Chair

    Arjun Balar, MD - Innovative Treatments for Bladder Cancer: Thoughts From the Chair

    Go online to PeerView.com/YFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this expert-led bladder cancer program, Dr. Arjun Balar discusses recent updates from the 2020 American Society of Clinical Oncology Annual Meeting and reviews new evidence on the continuing integration of novel therapeutics, including immunotherapy, targeted agents, and antibody-based approaches, across a wide range of bladder cancer treatment settings. Upon completion of this activity, participants should be better able to: Discuss the current therapeutic role of novel agents in advanced bladder cancer over multiple lines of treatment and across patient populations, Summarize updated evidence about the use of novel therapies, including immune checkpoint inhibitors, targeted agents, antibody-drug conjugates, and gene therapy across the spectrum of bladder cancer settings, Recommend patient-appropriate novel therapeutics for the management of bladder cancer, Manage unique adverse events associated with novel immune-, targeted-, antibody-, and gene therapy-based treatments for bladder cancer.

    • 25 min
    Sagar Lonial, MD, FACP - Fueling Innovation in Multiple Myeloma: Thoughts From the Chair

    Sagar Lonial, MD, FACP - Fueling Innovation in Multiple Myeloma: Thoughts From the Chair

    Go online to PeerView.com/CSW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in multiple myeloma treatment, including highlights from the 2020 American Society of Clinical Oncology Annual Meeting; the expert focuses on important questions related to primary therapy in myeloma, including triplet and quadruplet therapy, as well as advances with antibody platforms, cellular therapy, and targeted agents in relapsed disease. Upon completion of this activity, participants should be better able to: Discuss updated practice guidelines and new efficacy and safety findings on the use of novel immunomodulating agents, proteasome inhibitors, antibodies, cell therapy, and targeted agents in the myeloma setting, Integrate novel therapeutics into the management of newly diagnosed myeloma according to transplant eligibility, Develop safe, personalized therapeutic platforms for patients with pretreated myeloma, including patients with an early relapse or those with heavily pretreated disease, Manage therapeutic safety, dosing, and monitoring considerations with novel treatment platforms in multiple myeloma.

    • 35 min

Customer Reviews

4.2 out of 5
6 Ratings

6 Ratings

Top Podcasts In Science

Listeners Also Subscribed To